debt_leverage_profile
Medtronic-acquired entity; post-acquisition leverage absorbed into Medtronic's ~$20B long-term debt; standalone MiniMed leverage not separately disclosed
Inferred
Agent_Inference
interest_rate_sensitivity
As Medtronic subsidiary, interest rate exposure managed at parent level; 20bp rate rise adds ~$40M annual interest cost to Medtronic consolidated
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Semiconductor components sourced heavily from Taiwan (TSMC ecosystem); rare-earth materials for sensors concentrated in China
Inferred
Agent_Inference
international_expansion_readiness
Primary international markets: Europe (EUR), Japan (JPY), China (CNY); EUR/USD and JPY/USD volatility pose moderate repatriation risk
Inferred
Agent_Inference
geographic_footprint
US ~55% revenue; Europe ~25%; Asia-Pacific ~15%; currency devaluation risk highest in Japan and emerging Asian markets
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on proprietary sensor and infusion set supply chain; no single third-party vendor exceeds 30% but switching costs are very high
Inferred
Agent_Inference
business_model_type_primary
Medical device hardware and consumables manufacturer; cloud dependency minimal for core device function; data platform secondary
Inferred
Agent_Inference
business_model_type_secondary
CareLink cloud platform for data management; AWS/Azure disruption would impair data services but not core insulin delivery hardware
Inferred
Agent_Inference
switching_cost_profile
High API coupling risk via CareLink and CGM integrations; patients face 6-12 month retraining/recertification barriers to switch systems
Inferred
Agent_Inference
howey_test_risk_index
Revenue from device sales and consumables; no investment contract structure; Howey Test risk essentially zero — not a security
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Stores sensitive health/glucose data; GDPR exposure significant in EU; CCPA applies to California patients; FDA cybersecurity regulations add layer
Inferred
Agent_Inference
antitrust_exposure_flag
Medtronic holds ~35-40% global insulin pump market share; DOJ/EU scrutiny possible; interoperability restrictions have drawn regulatory attention
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~60% recurring (consumables: infusion sets, reservoirs, CGM sensors on 90-day cycles); ~40% transactional (hardware pump sales)
Inferred
Agent_Inference
monetization_vector
Razor-and-blade model; initial pump hardware sale anchors recurring high-margin consumable supply revenue stream
Inferred
Agent_Inference
pricing_architecture
Premium pricing sustained by clinical outcomes data and FDA clearances; payer reimbursement dependency creates price ceiling risk if CMS cuts DME rates
Inferred
Agent_Inference
pricing_power_rating
Moderate-high; reimbursement-constrained but brand and outcomes data support pricing; generic consumable competition emerging at 10-20% discount
Inferred
Agent_Inference
target_gross_margin_bracket
54.2% Gross Margin (Strong (40-60%))
High
SEC-XBRL
churn_vulnerability_index
Minimal free-rider leakage; consumables require proprietary hardware lock-in; off-label substitution risk low due to FDA device compatibility rules
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth largely sublinear to headcount; manufacturing automation and consumable volume scaling drive operating leverage beyond initial R&D investment
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of incremental consumable revenue very low (~15-20% COGS); hardware requires capital investment but consumable attach rate drives margin expansion
Inferred
Agent_Inference
franchise_compliance_risk
Not a franchise model; direct sales and distributor network; distributor compliance risk moderate in emerging markets but not franchise-specific
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC likely improves via payer channel bundling; per-patient LTV estimated $8,000-$15,000 over device lifetime including consumables
Inferred
Agent_Inference
network_effect_present
Weak direct network effects; indirect effects via CareLink data ecosystem improving algorithm performance; not a true platform network business
Inferred
Agent_Inference
asset_efficiency_ratio
-4.1% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Tier 1 recession resistant; Type 1 diabetes management is non-discretionary; insulin pump therapy clinically mandated regardless of economic cycle
Inferred
Agent_Inference
customer_segment_primary
Type 1 diabetes patients (primary); commercial insurance and Medicare/Medicaid as effective payer-customers driving reimbursement concentration risk
Inferred
Agent_Inference
customer_segment_secondary
Type 2 insulin-dependent diabetes patients (growing segment); endocrinologists and hospital systems as key referral and procurement decision-makers
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
7.2% CapEx / Revenue (Moderate-CapEx)
High
SEC-XBRL
sec_cik
0002062583
High
SEC-EDGAR
ticker
MMED
High
SEC-EDGAR